BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CVS Health is projecting another year of solid earnings growth, announcing that its expected 2026 profit will surpass both Wall Street forecasts and its own 2025 earnings outlook. The update, shared during the company’s investor day, underscores the steady progress of its ongoing turnaround strategy led by Chief Executive David Joyner.
Joyner emphasized that CVS has delivered on its commitments throughout the year and will now concentrate on improving consumer experiences and rebuilding trust—an area he described as a major challenge in today’s healthcare marketplace. As part of this effort, the company unveiled a new consumer app designed to integrate CVS services and offer new revenue opportunities for partners.
Shares of CVS climbed nearly 5% to $80.17 in morning trading following the announcement, extending a year of strong market performance. The stock has surged more than 70% in 2025 as the company implemented sweeping changes, including cost reductions, exits from underperforming markets, and enhancements to leadership to restore investor confidence.
Chief Financial Officer Brian Newman highlighted the company’s strong finish to 2025, stating that CVS expects “another year of strong earnings growth in 2026.” The company forecast adjusted earnings between $7.00 and $7.20 per share for 2026, slightly above consensus expectations of $7.16 per share.
While CVS anticipates up to $400 billion in revenue next year—short of analysts’ projected $419.26 billion—the company expects growth momentum to be driven by improved margins in its Aetna insurance arm and CVS Caremark pharmacy benefit management business. CVS also reiterated plans to exit the Affordable Care Act insurance market in 2026 due to rising medical costs.
Additionally, CVS raised its 2025 profit guidance to between $6.60 and $6.70 per share, marking its fourth increase this year. Analysts at Leerink Partners noted that CVS’ near-term performance supports a strong long-term recovery story for the healthcare conglomerate.
